目的 研究乙醛脱氢酶1(aldehyde dehydrogenase 1,ALDH1)和分化簇133(cluster of differentiation 133,CD133)在大肠癌中的表达,探讨其与大肠癌发生、发展及预后的关系。方法 采用免疫组织化学方法检测60例大肠癌、25例大肠腺瘤和20例正常大肠黏膜组织中ALDH1和CD133的表达,并分析其与临床病理参数和预后的关系。结果 大肠癌组织中ALDH1及CD133的表达率(78.3%,75.0%)明显高于大肠腺瘤(54.5%,48.0%)和正常大肠黏膜组织(15.0%,10.0%),每两组之间比较差异有统计学意义 (P<0.05) 。ALDH1的表达与大肠癌的浸润深度、TNM分期、淋巴结转移呈正相关 (P<0.05) ,与分化程度呈负相关 (P<0.05)。CD133的表达与大肠癌的浸润深度、淋巴结转移、TNM分期呈正相关 (P<0.05)。ALDH1和CD133在大肠癌中的表达呈正相关 (P<0.05)。ALDH1及CD133表达阳性的患者,其5年生存率低于表达阴性者 (P<0.05)。结论 ALDH1及CD133表达升高与大肠癌的发生、发展显著相关,有可能作为判定大肠癌预后的指标之一。
Abstract
Objective To study the expressions of ALDH1 and CD133 in colorectal carcinoma and their correlations with the occurrence, development and prognosis of colorectal carcinoma.Methods The expressions of ALDH1 and CD133 in 60 cases of colorectal carcinoma, 25 cases of colorectal adenomas and 20 cases of normal colorectal tissues were detected using immunohistochemical methods, and their association with clinicopathological parameters and prognosis was analyzed.Results The positive rate of ALDH1 and CD133 in colorectal carcinoma (78.3%,75.0%) was significantly higher than that in colorectal adenomas (54.5%,48.0%) and normal colorectal tissues (15%,10%) (P<0.05). The expression of ALDH1 was positively correlated with the depth of invasion, TNM stage and lymph node metastasis (P>0.05), but negatively with the degree of differentiation (P>0.05) in colorectal carcinoma. The expression of CD133 in colorectal carcinoma was positively correlated with the depth of invasion, lymph node metastasis and TNM staging (P<0.05). There was a positive correlation between the expressions of ALDH1 and CD133 in colorectal carcinoma (P<0.05). The 5-year survival rate of ALDH1 and CD133 positive patients was significantly lower than that of negative patients (P<0.05).Conclusions The increased expressions of ALDH1 and CD133 are significantly related to the occurrence and development of colorectal carcinoma and may be used as an indicator of the prognosis of colorectal carcinoma.
关键词
乙醛脱氢酶1 /
分化簇133 /
大肠癌 /
预后
Key words
aldehyde dehydrogenase 1 /
cluster of differentiation 133 /
colorectal carcinoma /
prognosis
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Fabišková K, Behulová R L, Repiska V. Molecular biomarkers in the diagnostic of patients with colorectal cancer[J]. Neuro Endocrinol Lett,2019,40(5):215-221.
[2] Cheng Z, Shao X, Xu M, et al. ENO1 acts as a prognostic biomarker candidate and promotes tumor growth and migration ability through the regulation of Rab1A in colorectal cancer[J]. Cancer Manag Res,2019,11(26):9969-9978.
[3] Hale D, Ozgecan D, Bugra T G, et al. Prognostic value of aldehyde dehydrogenase 1 (ALDH1) in invasive breast carcinomas[J]. Bosn J Basic Med Sci,2018,18(4):313-319.
[4] Shinichiro T, Satoshi N, Kenji O, et al. Serum deprivation response protein regulates aldehyde dehydrogenase 1 through integrin-linked kinase signaling in endometrioid carcinoma cells[J]. Cancer Sci,2019,110(5): 1804-1813.
[5] Hideki I, Li Y Y, Masami S, et al. Recycling endosomal CD133 functions as an inhibitor of autophagy at the pericentrosomal region[J]. Sci Rep,2019,9(2):2236-2254.
[6] Tian S, Xing Y N, Xia P. The prognostic roles of circulating ALDH1+ tumor cell in the patients with non-small cell lung cancer[J]. Biosci Rep,2018,38(5): 1-7.
[7] Paige M G, Aaron M L. The role of CD133 in cancer: a concise review[J]. Clin Transl Med,2018,7(1): 18-32.
[8] Xing P, Dong H, Liu Q, et al. ALDH1 expression and vasculogenic mimicry are positively associated with poor prognosis in patients with breast cancer[J]. Cell Physiol Biochem, 2018,49(3):961-970.
[9] Lee A, Won K Y, Lim S J, et al. ALDH1 and tumor infiltrating lymphocytes as predictors for neoadjuvant chemotherapy response in breast cancer[J]. Pathol Res Pract,2018,214(5):619-624.
[10] Yang C K, Wang X K, Liao X W, et al. Aldehyde dehydrogenase 1 (ALDH1) isoform expression and potential clinical implications in hepatocellular carcinoma[J]. PLoS One,2017,12(8): e0182208.
[11] Lauren M D, Michael F G, Brendan F, et al. Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC[J]. Oncotarget,2017,8(42): 72544-72563.
[12] Tsai M S, Chen W C, Lai C H, et al. Epigenetic therapy regulates the expression of ALDH1 and immunologic response: relevance to the prognosis of oral cancer[J]. Oral Oncology,2017,73(8):88-96.
[13] Tian S, Liu D H, Wang D, et al. Aldehyde dehydrogenase 1(ALDH1) promotes the toxicity of TRAIL in non-small cell lung cancer cells via post-transcriptional regulation of MEK-1 expression[J]. Cell Physiol Biochem, 2018, 51(1): 217-227.
[14] Nishikawa S, Konno M, Hambe A, et al. Aldehyde dehydrogenase high gastric cancer stem cells are resistant to chemotherapy[J]. Int J Oncol,2013,42(4):1437-1442.
[15] Zhu B, Zhou L, Lan Y, et al. Evaluation of the correlation of vasculogenic mimicry, ALDH1, KAI1 and microvessel density in the prediction of metastasis and prognosis in colorectal carcinoma[J]. BMC Surg,2017,17(47):1-9.
[16] Chen Y L, Lin P Y, Ming Y Z, et al. The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients[J]. BMC Cancer,2017,17(7):474-483.
[17] Weng C C, Kuo K K, SU H T, et al. Pancreatic tumor progression associated with CD133 overpression: involvement of increased TERT expression and epidermal growth factor receptor-dependent Akt activation[J]. Pancreas,2016,45(3):443-457.
[18] Geou Y L. CD133 as a regulator of cancer metastasis through the cancer stem cells[J]. Int J Biochem Cell Biol,2019,106(1):1-7.
PDF(1202 KB)
